GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Italy Fines Apple €98.6 Million Over App Store Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
CRANBURY, N.J., Feb. 06, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY on Thursday, February 16, 2017 at 11 a.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sid Dinsay [email protected] (646) 381-9017
